Last updated: May 14, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT05874414 | 1, 2 | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Autophagy and MEK -- small molecule inhibitors |
| NCT05568680 | 1 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Mesothelin -- KIR-CAR T cell therapy |
| NCT07582315 | 3 | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) | Unknown mechanism |
| NCT06501625 | 1, 2 | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation | IDH1 -- small molecule inhibitor; PD-L1 -- immune checkpoint inhibitor; DNA synthesis -- chemotherapy |
| NCT06282575 | 3 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | HER2 -- bispecific antibody (Zanidatamab) + chemotherapy + PD-1/PD-L1 -- immune checkpoint inhibitors |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 12 |
| Tianjin Medical University Cancer Institute and Hospital | 8 |
| Shanghai Zhongshan Hospital | 6 |
| M.D. Anderson Cancer Center | 6 |
| AstraZeneca | 6 |
Countries/regions with the most active trial sites for cholangiocarcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Mar 27, 2026 | NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | IRAK4 -- small molecule inhibitor (Emavusertib) + chemotherapy (Gemcitabine, Cisplatin) + PD-L1 -- immune checkpoint inhibitor (Durvalumab) |
| Jan 30, 2026 | NCT07392541 | Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer | PD-L1 -- immune checkpoint inhibitor + chemotherapy + HMG-CoA reductase inhibitor (statin) |
| Nov 4, 2025 | NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | PD-1 + CTLA-4 -- dual immune checkpoint inhibitors + radiotherapy (PULSAR) |
| Oct 22, 2025 | NCT07213791 | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Fibroblast activation protein (FAP) -- monoclonal antibody |
| Aug 26, 2025 | NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | CLDN1 -- monoclonal antibody or targeted agent (ALE.P03) |
| Jun 24, 2025 | NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | HER2 -- monoclonal antibody (KJ015) |
| May 27, 2025 | NCT06564623 | Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | Tumor driver oncogenes -- peptide vaccine plus immune checkpoint inhibitors |
Want trials matched to a specific patient profile?
Enter biomarkers, stage, and prior treatments — get ranked trial matches with eligibility breakdown in minutes.
Find Matching TrialsSource: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.